David Thompson, Ph.D., serves as Inotiv’s senior director of mechanistic pharmacology and toxicology (MP&T), a position he has held since December of 2019. He leads a team focused on using state-of-the-art in vitro molecular and cell-based tools to address pharmacological and toxicological issues. In this role, he guides the development of new assays, capabilities, and expanded offerings for clients. This allows Inotiv to offer new mechanistic insights into our clients’ concerns or issues. Given the diversity and novelty of the projects he heads, Dr. Thompson plays a key role in the Integrated Discovery Center, increasing collaborations between Inotiv’s groups and external teams.
Dr. Thompson comes well-prepared to his position at Inotiv. He has spent time as a researcher and/or manager at diverse institutions during his 35-year career. In industry, he worked as an investigative toxicologist at Searle/Monsanto, Pharmacia, and Pfizer pharmaceutical companies, as well as an R&D senior manager for an ADME/tox-focused group at Millipore Sigma prior to joining Inotiv. Before his time in industry, Dr. Thompson developed his research acumen in academia, spending a postdoctoral fellowship at the Karolinska Institute in Sweden, followed by a senior staff fellowship at the National Institute of Environmental Health Sciences. He served as a faculty member at Texas A&M University College of Medicine in the department of Medical Pharmacology and Toxicology prior to moving to the pharmaceutical industry. From these experiences, Dr. Thompson has the depth of both research and industry expertise to develop whatever in vitro assay an Inotiv client could need.